bristol myers squibb news - Search News

Prime, Bristol Myers Squibb

Seeking Alpha on MSN · 1d

Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates

Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal, Prime (PRME) will receive $55M upfront and the $55M investment.

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb

Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.

Business Insider · 1d

Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb

Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)

Seeking Alpha · 3d

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

MarketWatch · 1d

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies. In premarket trading, shares were up 20% to $4.

1d

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol Myers Squibb Wins Dismissal of $6.4 Billion Lawsuit Alleging Intentional Delay of Cancer Drug

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for ...

1don MSN

Bristol Myers gets $6.4B Celgene CVR case dismissed: report

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

4d

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

4d

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

15h

Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

4d

Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results